Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 3

1(25.0%)

Phase 4

1(25.0%)

4Total

N/A(2)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02936596Not ApplicableUnknown

Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome

Role: lead

NCT04933292Phase 4Unknown

A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome

Role: lead

NCT02917408Completed

Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital

Role: lead

NCT02874586Not ApplicableUnknown

Plasma Exchange Combination of Immunosuppressive Regimens for Auto-immune Hepatitis

Role: lead

NCT02878863Phase 3Withdrawn

Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis

Role: lead

All 5 trials loaded